Estrogens and tamoxifen do not only exert their effects at the genomic level, but also play a role at the cell membrane activating downstream signaling pathways. We recently characterized an estrogen receptor-positive epithelial murine breast cancer cell line, LM05-E. Utilizing this cell line and MCF-7 cells, we compared the non-genomic effects of estradiol and 4-OH-tamoxifen. We showed that, similar to estradiol, tamoxifen activated the MAPK/ERK 1/2 pathway; however, we did not find activation of PI3K/AKT by either estradiol or tamoxifen. Short-term treatments with estradiol stimulated, whereas tamoxifen inhibited cell proliferation. Using pharmacological inhibitors we showed that the effect of estradiol was mediated by the MAPK/ERK 1/2 pa...
AbstractThe effects of tamoxifen (TAM), a widely used agent in the treatment of breast cancer, were ...
SynthSys is a Centre for Integrative Systems Biology (CISB) funded by BBSRC and EPSRC, reference BB/...
Introduction Anti-oestrogens have been the mainstay of therapy in patients with oestrogen-receptor ...
Breast cancer is one of the most highly diagnosed cancers in women and the second largest cause of d...
Tamoxifen (Tam) is widely used in chemotherapy of breast cancer. It inhibits proliferation and induc...
Although Inflammatory Breast Cancer (IBC) is a rare and an aggressive type of locally advanced breas...
BackgroundThe sensitivity of estrogen receptor-positive breast cancers to tamoxifen treatment varies...
AbstractEstrogen receptor (ER) antagonists such as tamoxifen (Tam) have been used successfully to tr...
Background: Endocrine resistance is a common problem in estrogen receptor positive (ER+) breast canc...
Upon activation by estrogen, the Estrogen Receptor binds the chromatin and influ...
Although tamoxifen treatment is associated with improved survival in patients with estrogen receptor...
Estrogen receptors (ERs) mediate most of the biological effects of estrogen in mammary and uterine e...
International audienceEndocrine therapies targeting oestrogen signalling have significantly improved...
EGFR/MAPK signalling has been implicated in mediating tamoxifen-resistant breast cancer cell growth ...
We have previously demonstrated that oestrogen receptor α (ERα) modulates epidermal growth factor re...
AbstractThe effects of tamoxifen (TAM), a widely used agent in the treatment of breast cancer, were ...
SynthSys is a Centre for Integrative Systems Biology (CISB) funded by BBSRC and EPSRC, reference BB/...
Introduction Anti-oestrogens have been the mainstay of therapy in patients with oestrogen-receptor ...
Breast cancer is one of the most highly diagnosed cancers in women and the second largest cause of d...
Tamoxifen (Tam) is widely used in chemotherapy of breast cancer. It inhibits proliferation and induc...
Although Inflammatory Breast Cancer (IBC) is a rare and an aggressive type of locally advanced breas...
BackgroundThe sensitivity of estrogen receptor-positive breast cancers to tamoxifen treatment varies...
AbstractEstrogen receptor (ER) antagonists such as tamoxifen (Tam) have been used successfully to tr...
Background: Endocrine resistance is a common problem in estrogen receptor positive (ER+) breast canc...
Upon activation by estrogen, the Estrogen Receptor binds the chromatin and influ...
Although tamoxifen treatment is associated with improved survival in patients with estrogen receptor...
Estrogen receptors (ERs) mediate most of the biological effects of estrogen in mammary and uterine e...
International audienceEndocrine therapies targeting oestrogen signalling have significantly improved...
EGFR/MAPK signalling has been implicated in mediating tamoxifen-resistant breast cancer cell growth ...
We have previously demonstrated that oestrogen receptor α (ERα) modulates epidermal growth factor re...
AbstractThe effects of tamoxifen (TAM), a widely used agent in the treatment of breast cancer, were ...
SynthSys is a Centre for Integrative Systems Biology (CISB) funded by BBSRC and EPSRC, reference BB/...
Introduction Anti-oestrogens have been the mainstay of therapy in patients with oestrogen-receptor ...